nitrendipine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
calcium channel blockers, nifedipine derivatives 1947 39562-70-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nitrendipine
  • nitrendipin
  • nitrepin
A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.
  • Molecular weight: 360.37
  • Formula: C18H20N2O6
  • CLOGP: 3.73
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 1
  • TPSA: 107.77
  • ALOGS: -4.41
  • ROTB: 7

Drug dosage:

DoseUnitRoute
20 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.92 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 16.50 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 6.10 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 25 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 8.20 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1985 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
General physical health deterioration 76.87 33.51 55 2200 115714 46568093
Antinuclear antibody negative 71.35 33.51 12 2243 228 46683579
Hypertension 68.34 33.51 64 2191 196292 46487515
Herpes simplex reactivation 66.49 33.51 12 2243 348 46683459
Coombs positive haemolytic anaemia 65.53 33.51 12 2243 378 46683429
Fall 58.04 33.51 75 2180 329022 46354785
Product prescribing error 57.37 33.51 25 2230 20022 46663785
Gastritis haemorrhagic 50.89 33.51 12 2243 1314 46682493
Antiphospholipid syndrome 47.85 33.51 12 2243 1700 46682107
Complex regional pain syndrome 45.61 33.51 12 2243 2054 46681753
Hypertensive angiopathy 44.18 33.51 7 2248 90 46683717
Anxiety disorder 43.62 33.51 13 2242 3498 46680309
Hypertensive crisis 39.01 33.51 17 2238 13598 46670209
Premature baby 37.37 33.51 18 2237 18094 46665713
Lymphopenia 37.11 33.51 17 2238 15276 46668531
Hyperlipidaemia 36.98 33.51 18 2237 18521 46665286
Syncope 36.01 33.51 34 2221 104769 46579038
Erysipelas 34.93 33.51 13 2242 6925 46676882

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product prescribing error 73.18 26.80 31 1981 16702 29933764
Syncope 60.40 26.80 48 1964 84855 29865611
Dizziness 59.56 26.80 69 1943 194840 29755626
Osteochondrosis 38.01 26.80 9 2003 719 29949747
Postrenal failure 36.94 26.80 8 2004 427 29950039
General physical health deterioration 36.59 26.80 39 1973 99905 29850561

Pharmacologic Action:

SourceCodeDescription
ATC C08CA08 CARDIOVASCULAR SYSTEM
CALCIUM CHANNEL BLOCKERS
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
Dihydropyridine derivatives
ATC C09BB06 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors and calcium channel blockers
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002121 Calcium Channel Blockers
MeSH PA D000077264 Calcium-Regulating Hormones and Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D014665 Vasodilator Agents
CHEBI has role CHEBI:35620 vasodilator
CHEBI has role CHEBI:35674 antihypertensive
CHEBI has role CHEBI:38215 calcium channel blockers

Drug Use (View source of the data)

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.37 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Voltage-dependent L-type calcium channel subunit alpha-1D Ion channel GATING INHIBITOR IC50 8.40 IUPHAR IUPHAR
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel BLOCKER UNKNOWN SCIENTIFIC LITERATURE
Cytochrome P450 2C9 Enzyme IC50 6.52 DRUG MATRIX
Cytochrome P450 2C19 Enzyme IC50 5.52 DRUG MATRIX
Voltage-dependent T-type calcium channel subunit alpha-1H Ion channel IC50 5.06 WOMBAT-PK
Transthyretin Secreted IC50 5.92 WOMBAT-PK
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 4.44 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5 CHEMBL
Voltage-dependent calcium channel gamma-1 subunit Ion channel WOMBAT-PK
Adenosine receptor A3 GPCR Ki 5.08 WOMBAT-PK
Voltage-dependent L-type calcium channel subunit alpha-1F Ion channel GATING INHIBITOR IC50 6 IUPHAR
Intermediate conductance calcium-activated potassium channel protein 4 Ion channel BLOCKER IC50 7.60 IUPHAR
Platelet-activating factor receptor GPCR Ki 4.13 CHEMBL
Adenosine receptor A2a GPCR Ki 4.64 CHEMBL
Adenosine receptor A1 GPCR Ki 5.05 CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel GATING INHIBITOR IC50 6 IUPHAR
Voltage-dependent L-type calcium channel subunit alpha-1S Ion channel GATING INHIBITOR IC50 6 IUPHAR

External reference:

IDSource
N0000167238 NUI
D00629 KEGG_DRUG
C0028127 UMLSCUI
CHEBI:7582 CHEBI
CHEMBL251230 ChEMBL_ID
CHEMBL268609 ChEMBL_ID
CHEMBL475534 ChEMBL_ID
D009568 MESH_DESCRIPTOR_UI
DB01054 DRUGBANK_ID
2334 IUPHAR_LIGAND_ID
4739 INN_ID
9B627AW319 UNII
4507 PUBCHEM_CID
7441 RXNORM
005383 NDDF
444757009 SNOMEDCT_US

Pharmaceutical products:

None